Exscientia announces collaboration with charitÉ to advance development of precision medicine platform

Oxford, england & berlin, germany--(business wire)--exscientia plc (nasdaq: exai) today announced a new collaboration with charitÉ – universitÄtsmedizin berlin (charitÉ) to utilise exscientia's ai-driven precision medicine platform in haematological cancers. under the collaboration, charitÉ will evaluate the potential of exscientia's precision medicine platform to select better treatments and improve outcomes for patients with haematological cancers.
EXAI Ratings Summary
EXAI Quant Ranking